Search Medical Condition
Please enter condition
Please choose location from dropdown

Holstebro, Denmark Clinical Trials

A listing of Holstebro, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Quality of Life the Danish Multiple Myeloma Patients

Multiple myeloma is an incurable malignancy of the bone marrow and the second most common type of haematological cancer. In Denmark, about 320 patients are diagnosed annually with multiple myeloma, and the cancer often affects older people, but 30 % of the patients living with MM are of working age. ...

Phase N/A

0.0 miles

Learn More »

Handling Oxygenation Targets in the Intensive Care Unit

Acutely ill adults with hypoxaemic respiratory failure admitted to the intensive care unit (ICU) are at risk of life-threatening hypoxia, and thus oxygen is administered. However, the evidence on the optimal level of oxygenation is of low quantity and quality with no firm evidence for benefit or harm. Importantly, liberal ...

Phase

2.3 miles

Learn More »

Cost Efficacy of a Clinical Pathway to Patients Undergoing Hip and Knee Replacement Surgery

BACKBROUND Hip and knee replacement are commonly performed surgical procedures, with more than 800,000 hip operations carried out worldwide each year and with almost 550 hip and knee replacements each year in Ringkoebing County. The main indicators for total hip or knee replacement are intractable pain and/or limitation of function ...

Phase N/A

2.3 miles

Learn More »

An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will compare the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, phase 2 study that, on the basis ...

Phase

2.3 miles

Learn More »

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

This study aims to assess the optimal duration of nilotinib 300 mg BID consolidation treatment, in order that patients remain in treatment-free remission (MR4.0) 12 months after starting the Treatment-Free Remission (TFR) phase of the study. Rationale CP-CML patients who have received 2 or more calendar years of first-line imatinib ...

Phase

2.3 miles

Learn More »

Improvement of Implant Survival in Total Joint Arthroplasty of the Trapeziometacarpal Joint

The study evaluates implant survival and clinical outcome in total joint arthroplasty of the TMC joint. Different implant designs are included in the study both cemented and uncemented implants. Also the influence of patient factors and surgical technique on implant survival is investigated. The primary outcome is implant migration and ...

Phase N/A

2.3 miles

Learn More »

Microbiology of Para- og Retropharyngeal Abscess

Patients Sixty patients aged 18 years or older with para- or retropharyngeal abscess and 12 patients with neck abscess without relation to the pharynx or salivary glands (controls) will be included at five Danish centers. Estimated time of inclusion: Four years. Data Symptoms, findings, and other relevant information will be ...

Phase N/A

2.3 miles

Learn More »

Length of Stay and Complications in High-risk Patients Receiving Fast-track Total Hip (THA) or Knee- Alloplasty (TKA)

Preoperative risk assessment is well established and repeatedly demonstrated to be related to adverse postoperative outcomes regarding all organ functions. However, all evidence is based upon conventional care programs and none has been done on fast-track surgery, neither in total hip arthroplasty (THA) or total knee arthroplasty (TKA). The purpose ...

Phase N/A

2.3 miles

Learn More »

Early Versus Late FDG-PET/CT in Bladder Cancer

Background: Approximately 900 patients are diagnosed with invasive bladder cancer (BC) in Denmark each year. Approximately 50% are diagnosed with non-muscle invasive BC (T1) and approximately 50% are diagnosed with a muscle invasive BC (T2-4). Male-female ratio is 75% - 25% and the median age among all diagnosed patients at ...

Phase N/A

2.3 miles

Learn More »

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropenias and infections with FCR, bendamustine and rituximab (BR) must be considered in patients ...

Phase

2.3 miles

Learn More »